Mithra Releases 2020 Annual Report and Invitation to its Securities holders' Meeting

Liege, Belgium, 20 April 2021 – 7:30 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women's Health today announces the publication of its 2020 Annual Report and the invitation to its ordinary and extraordinary general meeting of securities holders.

2020 Annual Report

The Annual Report which outlines Mithra's achievements in 2020 includes the following information:

Overview of Mithra's R&D pipeline and Letter to Shareholders;
Highlights of Mithra's Strategy and Outlook for 2021;
Management Report;
Remuneration Report;
Financial statements and notes.

The Annual Report is available in English and French and can be read (or downloaded in PDF) on the website report2020.mithra.com or on investors.mithra.com. In case of interpretation differences, the French version will prevail.

General Shareholders' meeting

Mithra is pleased to invite its securities holders to its ordinary and extraordinary general shareholder's meeting that will be held on Thursday May 20 2021 at 2:00 PM (CEST).

The notice for the General Shareholder's Meeting including a description of the formalities to participate in the Meeting is available on the website investors.mithra.com.

Exceptional organisational arrangements due to Covid-19

In the context of the COVID-19 pandemic, the protection measures adopted by the Belgian Government, such as limiting the number of people attending meetings and ensuring a distance of 1.5 meters between each person, may still be in application on May 20, 2021 for the ordinary and extraordinary shareholders' meetings. These measures are in the interest of the health of our shareholders, as well as of the Company's staff and other persons responsible for organizing the shareholders' meetings. Furthermore, it cannot be excluded that the Belgian government will prescribe additional measures.

Therefore, the Company recommends that Company's shareholders who wish to participate to the shareholders' meetings do not attend in person and use, to the extent possible, the right to vote by mail or by proxy with specific voting instructions for each proposed decision granted to Fanny Rozenberg, Secretary of the Board of Directors. The Company will only give access to the shareholders' meetings to security holders, proxies and all other persons in strict compliance with the governmental measures and recommendations applicable at the time of the shareholders' meetings. In addition, the Company's security holders are encouraged to exercise their right to ask written questions concerning agenda items of the shareholders' meetings'.

The Company will also set up a video conference to enable duly registered securities holders of the Company who have completed and returned the notice of participation to the Company, to remotely attend shareholders' meetings. Videoconferencing will not be considered an digital communication way for attending and voting at shareholders' meetings, as referred to in Provision 7:137 of the Companies and Associations Code, but will be an additional tool for securities holders to attend shareholders' meetings. The Company will closely monitor the situation and any applicable measure and may provide other relevant updates for the Ordinary and Extraordinary Shareholders' Meetings on the Company's website (investors.mithra.com).

All procedures for attending the ordinary and extraordinary shareholders' meetings are indicated in the present meeting's invitation.

Admission requirements

As referred in the meeting's invitation published in the Belgian press, the right to participate in the general shareholder's meeting and to vote is subject to the prior registration of the shares under the shareholder's name on 6 May 2021 at midnight (CET) (the "Record Date"), either by way of registration on the company's share register, or either by way of registration in book entry form in an account held with a settlement institution or a certified account holder, without taking into account the number of shares held by the shareholder at the day of the general meeting. Only persons who are shareholders on the Record Date are entitled to vote at the general meeting.

A certification is delivered to the shareholder by the settlement institution or certified account holder which certifies the number of dematerialized shares registered in its accounts under the name of the shareholder on the Record Date, for which the shareholder has expressed its intention to participate in the general meeting.

The shareholder indicates his willingness to participate in the General Meeting by 14 May 2021 at the latest. This must be done by email to [email protected], or by mail marked for the attention of Mithra Pharmaceuticals SA, Corporate Secretary, 5, rue Saint-Georges à 4000 Liège.

Right to ask questions

The directors answer questions that are asked by the shareholders, in writing before the meeting, concerning their report or the agenda, in accordance with legal provisions. These questions may be asked prior to the General Meeting by email to the address [email protected] or by mail marked for the attention of Mithra Pharmaceuticals SA, Corporate Secretary, 5, rue Saint-Georges à 4000 Liège. These questions must be received by the Company on 14 May 2021 at the latest.

Further information relating to the abovementioned right and the modalities for exercising them are available on the Company's website (www.mithra.com).

Proxies

Any shareholder who wish to vote for that meeting shall be represented by a proxy holder determined by the Company.

Shareholders wishing to be represented must send the completed and signed¹ proxy form to the Company on 14 May 2021 at the latest, by email, fax or mail to Mithra's headquarter.

Shareholders wishing to vote by mail must send the completed and signed¹ proxy form to the Company on 14 May 2021 at the latest, by email, fax or mail to Mithra's headquarter.

Further information on the exercise of this right is available on the Company's website (www.mithra.com). The proxy and voting forms may be obtained on the Company's website (www.mithra.com) or upon request at the Company's registered office, or by email to [email protected].

Shareholders wishing to be represented must comply with the registration and confirmation procedure described above.

Available documents

All documents concerning the general meeting that are required by law to be made available to shareholders as well as the text of the amended articles of association following the approval of the amendments proposed on the agenda may be consulted on the Company's website (www.mithra.com) as from 20 April 2021. As from the same date, shareholders have the right to consult these documents on business days and during normal office hours, at the Company's registered office and/or, upon display of their securities, obtain copies of these documents free of charge.

Requests for copies may also be made, free of charge, by mail (writing) marked for the attention Mithra Pharmaceuticals SA, Corporate Secretary, 5, rue Saint-Georges à 4000 Liège, or by email to [email protected].

********

For more information, please contact:

Benoît Mathieu (IRO) : +32 473 35 80 18 - [email protected] Maud Vanderthommen (Press) : +32 473 58 61 04 – [email protected]

About Mithra

Mithra (Euronext: MITRA) is a Belgian biotech company dedicated to transforming Women's Health by offering new choices through innovation, with a particular focus on contraception and menopause. Mithra's goal is to develop products offering better efficacy, safety and convenience, meeting women's needs throughout their life span. Mithra explores the potential of the unique native estrogen Estetrol in a wide range of applications in women health and beyond (Covid-19, neuroprotection…). Mithra also develops and manufactures complex therapeutics in the areas of contraception, menopause and hormone-dependent cancers. It offers partners a complete spectrum of research, development and specialist manufacturing at its technological platform Mithra CDMO. Active in more than 100 countries around the world, Mithra has an approximate headcount of 300 staff members and is headquartered in Liège, Belgium. www.mithra.com

Important information

¹ The form must be signed in writing or electronically, with a qualified electronic signature within the meaning of Regulation (EU) No 910/2014 of the European Parliament and of the Council of 23 July 2014 on electronic identification and trust services for electronic transactions in the internal market and repealing Directive 1999/93/EC, as amended

The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the words "believes", "estimates," "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The Company's actual results may differ materially from those predicted by the forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.

News Alerts

Subscribe to our mailing list on investors.mithra.com to receive our press releases by email or follow us on our social media : Linkedin • Twitter • Facebook

AI Terminal

Mithra Pharmaceuticals S.A.

3977_iss_2021-04-20_1e1a990d-28d3-4b1a-a733-46ce8b0be4bf.pdf